The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Open accessAbstract
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of the genome and transcriptome from representative numbers of patients. We present an integrated analysis of copy number and gene expression in a discovery and validation set of 997 and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants (copy number variants and single nucleotide polymorphisms) and acquired somatic copy number aberrations (CNAs) were associated with expression in ~40% of genes, with the landscape dominated by cis- and trans-acting CNAs. By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and MAP2K4. Unsupervised analysis of paired DNA–RNA profiles revealed novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort. These include a high-risk, oestrogen-receptor-positive 11q13/14 cis-acting subgroup and a favourable prognosis subgroup devoid of CNAs. Trans-acting aberration hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the ‘CNA-devoid’ subgroup and a basal-specific chromosome 5 deletion-associated mitotic network. Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, numerous research efforts are focused on utilizing genetic data and artificial intelligence algorithms to develop diagnostic models to enhance the clinical efficiency and accuracy of breast cancer diagnosis [109,110,111].”
From A Comprehensive Review on Synergy of Multi-Modal Data and AI Technologies in Medical Diagnosis (2024) · cites this paper as [111]
In the citing paper
“This framework was also employed for a landmark study which used genomic and transcriptomic data from 2,000 breast tumours and discovered novel subgroups amongst them (Curtis et al., 2012).”
From Using machine learning approaches for multi-omics data analysis: A review (2021) · cites this paper as Curtis et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Self-citationNishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R. J., Hastie, T. J., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,931
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,411
Self-citationGenomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,309
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T., Shih, I., Mao, T., Nakayama, K., Roden, R. B. S., Glas, R., Slamon, D. J., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,218
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,028
Breast tumor microenvironment structures are associated with genomic features and clinical outcome
Danenberg, E., Bardwell, H. A., Zanotelli, V. R., Provenzano, E., Chin, S., Rueda, O. M., Green, A. R., Rakha, E. A., Aparicio, S. A. J. R., Ellis, I. O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01041-y · Cited by 273
Self-citationSingle-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I. S., Sampath, D., Giltnane, J. M., Lacap, J. A., Crocker, L., Young, A. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 272
Ha, G., Roth, A. J. L., Lai, D., Bashashati, A., Ding, J., Goya, R., Giuliany, R., Rosner, J., Oloumi, A., Shumansky, K., et al. (2012) · Genome Research · doi:10.1101/gr.137570.112 · Cited by 269
Self-citationHow Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M., & Sherman, M. E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju165 · Cited by 268
Dekkers, J. F., van Vliet, E. J., Sachs, N., Rosenbluth, J. M., Kopper, O., Rebel, H. G., Wehrens, E. J., Piani, C., Visvader, J. E., Veríssimo, C. S., et al. (2021) · Nature Protocols · doi:10.1038/s41596-020-00474-1 · Cited by 282
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Thomas, A., Routh, E. D., Pullikuth, A., Jin, G., Su, J., Chou, J. W., Hoadley, K. A., Print, C. G., Knowlton, N. S., Black, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490854 · Cited by 266
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S., Alférez, D., Aparicio, S. A. J. R., Behbod, F., Bentires‐Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 272
Self-citationThe androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven‐Law, G., Milioli, H. H., Roden, D. L., Jindal, S., Hui, M. N., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 261
Self-citationMultiBLUP: improved SNP-based prediction for complex traitsPreprint
Speed, D., & Balding, D. J. (2014) · Genome Research · doi:10.1101/gr.169375.113 · Cited by 271
Self-citationGatza, M. L., Silva, G. O., Parker, J. S., Fan, C., & Perou, C. M. (2014) · Nature Genetics · doi:10.1038/ng.3073 · Cited by 261
Brasó‐Maristany, F., Filosto, S., Catchpole, S., Marlow, R., Quist, J., Francesch-Domenech, E., Plumb, D. A., Zakka, L., Gazińska, P., Liccardi, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4198 · Cited by 253
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
Bonavita, E., Bromley, C. P., Jonsson, G., Pelly, V. S., Sahoo, S., Walwyn-Brown, K., Mensurado, S., Moeini, A., Flanagan, E., Bell, C. R., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.020 · Cited by 257
Pioneer factors as master regulators of the epigenome and cell fate
Balsalobre, A., & Drouin, J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00464-z · Cited by 251
Chiu, H., Somvanshi, S., Patel, E., Chen, T.-W., Singh, V., Zorman, B., Patil, S. L., Pan, Y., Chatterjee, S. S., Johnson, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.064 · Cited by 251
Wang, Y.-Q., Wang, P., Wang, Y.-T., Yang, G., Zhang, A., & Miao, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00055 · Cited by 251
Somatic TP53 Mutations in the Era of Genome SequencingPreprint
Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 256
Kim, J., Sharma, A., Dhar, S. S., Lee, S.-H., Gu, B., Chan, C., Lin, H., & Lee, M. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1896 · Cited by 249
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study
Kridel, R., Chan, F. C., Mottok, A., Boyle, M., Farinha, P., Tan, K. L., Meissner, B., Bashashati, A., McPherson, A., Roth, A. J. L., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002197 · Cited by 245
Self-citationThe lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression
Niknafs, Y. S., Han, S., Ma, T., Speers, C. W., Zhang, C., Wilder-Romans, K., Iyer, M. K., Pitchiaya, S., Malik, R., Hosono, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms12791 · Cited by 246
Role of p53 in breast cancer progression: An insight into p53 targeted therapy
Marvalim, C., Datta, A., & Lee, S. C. (2023) · Theranostics · doi:10.7150/thno.81847 · Cited by 259
A Comprehensive Review on Synergy of Multi-Modal Data and AI Technologies in Medical Diagnosis
Xu, X., Li, J., Zhu, Z., Zhao, L., Wang, H., Song, C., Chen, Y., Zhao, Q., Yang, J., & Pei, Y. (2024) · Bioengineering · doi:10.3390/bioengineering11030219 · Cited by 242
Mallini, P., Lennard, T. W. J., Kirby, J. A., & Meeson, A. P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.008 · Cited by 247
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 250
Understanding breast cancer – The long and winding road
Lukong, K. E. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.01.001 · Cited by 238
Pioneer transcription factors shape the epigenetic landscape
Mayran, A., & Drouin, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.001232 · Cited by 249
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
Kurtz, D. M., Esfahani, M. S., Scherer, F., Soo, J., Jin, M. C., Liu, C. L., Newman, A. M., Dührsen, U., Hüttmann, A., Casasnovas, O., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.011 · Cited by 240
Identification of Novel Genetic Markers of Breast Cancer Survival
Guo, Q. J., Schmidt, M. K., Kraft, P. L., Canisius, S., Chen, C., Khan, S., Tyrer, J. P., Bolla, M. K., Wang, Q., Dennis, J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv081 · Cited by 234
Virassamy, B., Caramia, F., Savas, P. S., Sant, S. A., Wang, J., Christo, S. N., Byrne, A., Clarke, K. A., Brown, E., Teo, Z. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.004 · Cited by 247
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome
Fumagalli, D., Gacquer, D., Rothé, F., Lefort, A., Libert, F., Brown, D. N., Kheddoumi, N., Shlien, A., Konopka, T., Salgado, R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.032 · Cited by 233
Chalise, P., & Fridley, B. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176278 · Cited by 239
Prat, A., Carey, L., Adamo, B., Vidal, M. J., Tabernero, J. M., Cortés, J., Parker, J. S., Perou, C. M., & Baselga, J. M. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju152 · Cited by 240
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P. K., & Leyland-Jones, B. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 237
State of the evidence 2017: an update on the connection between breast cancer and the environment
Gray, J., Rasanayagam, S., Engel, C. L., & Rizzo, J. (2017) · Environmental Health · doi:10.1186/s12940-017-0287-4 · Cited by 245
Breast cancer quantitative proteome and proteogenomic landscape
Johansson, H. J., Socciarelli, F., Vacanti, N. M., Haugen, M. H., Zhu, Y., Siavelis, I., Fernandez-Woodbridge, A., Aure, M. R. R., Sennblad, B., Vesterlund, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09018-y · Cited by 233
Self-citationThe crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · The EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 235
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S. S., Persky, N. S., Marini, L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 232
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.007 · Cited by 241
Variable selection for generalized canonical correlation analysis
Tenenhaus, A., Philippe, C., Guillemot, V., Cao, K. L., Grill, J., & Frouin, V. (2014) · Biostatistics · doi:10.1093/biostatistics/kxu001 · Cited by 246
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 231
A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data
Li, Y., Kang, K., Krahn, J. M., Croutwater, N., Lee, K. C., Umbach, D. M., & Li, L. (2017) · BMC Genomics · doi:10.1186/s12864-017-3906-0 · Cited by 246
Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., Choudhury, A. D., Gydush, G., Reed, S. C., Rhoades, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0033 · Cited by 230
Self-citationMetabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
Gandhi, N. S., & Das, G. M. (2019) · Cells · doi:10.3390/cells8020089 · Cited by 237
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER
van den Beucken, T., Koch, E., Chu, K., Rupaimoole, R., Prickaerts, P., Adriaens, M. E., Voncken, J. W., Harris, A. L., Buffa, F. M., Haider, S. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6203 · Cited by 229
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238
Uncertainty as a Form of Transparency: Measuring, Communicating, and Using Uncertainty
Bhatt, U., Antorán, J., Zhang, Y., Liao, Q. V., Sattigeri, P., Fogliato, R., Melançon, G., Krishnan, R., Stanley, J., Tickoo, O., et al. (2021) · Proceedings of the 2021 AAAI/ACM Conference on AI, Ethics, and Society · doi:10.1145/3461702.3462571 · Cited by 300
Integrative pathway enrichment analysis of multivariate omics data
Paczkowska, M., Barenboim, J., Sintupisut, N., Fox, N. S., Zhu, H., Abd-Rabbo, D., Mee, M. W., Boutros, P. C., PCAWG Drivers and Functional Interpretation Working Group, Abascal, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13983-9 · Cited by 236
Erdal, E., Haider, S. A., Rehwinkel, J., Harris, A. L., & McHugh, P. J. (2017) · Genes & Development · doi:10.1101/gad.289769.116 · Cited by 225
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. (2014) · Genome biology · doi:10.1186/s13059-014-0431-1 · Cited by 229
Self-citationInhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
Granados-Principal, S. M., Liu, Y., Guevara, M. L., Blanco, E., Choi, D. S., Qian, W. P., Patel, T. A., Rodriguez, A. A., Cusimano, J. M., Weiss, H. L., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0527-x · Cited by 232
Burugu, S., Asleh, K., & Nielsen, T. O. (2016) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 234
Landscape of G-quadruplex DNA structural regions in breast cancer
Hänsel-Hertsch, R., Simeone, A., Shea, A., Hui, W. W. I., Zyner, K. G., Marsico, G., Rueda, O. M., Bruna, A., Martin, A., Zhang, X., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0672-8 · Cited by 223
Self-citationGenetic Susceptibility to Triple-Negative Breast Cancer
Purrington, K. S., Vachon, C. M., & Couch, F. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1699 · Cited by 229
Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific
Michea, P., Noël, F., Zakine, È., Czerwińska, U., Sirven, P., Abouzid, O., Goudot, C., Scholer‐Dahirel, A., Vincent‐Salomon, A., Reyal, F., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0145-8 · Cited by 231
Chung, S. J., Nagaraju, G. P., Nagalingam, A., Muniraj, N., Kuppusamy, P., Walker, A., Woo, J., Győrffy, B., Gabrielson, E., Saxena, N. K., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1332565 · Cited by 224
Barèche, Y., Buisseret, L., Gruosso, T., Girard, E., Venet, D., Dupont, F., Desmedt, C., Larsimont, D., Park, M., Rothé, F., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz208 · Cited by 221
Asleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 235
Master regulators of FGFR2 signalling and breast cancer risk
Fletcher, M. N. C., Castro, M. A. A., Wang, X., de Santiago, I., O’Reilly, M., Chin, S., Rueda, O. M., Caldas, C., Ponder, B. A. J., Markowetz, F. M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3464 · Cited by 226
Self-citationGenomic landscapes of breast fibroepithelial tumors
Tan, J. Y., Ong, C. K., Lim, W. K., Ng, C. C. Y., Thike, A. A., Ng, L. M., Rajasegaran, V., Myint, S. S., Nagarajan, S., Thangaraju, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3409 · Cited by 219
The Proteomic Landscape of Triple-Negative Breast Cancer
Lawrence, R., Perez, E. M., Hernández, D., Miller, C. P., Haas, K. M., Irie, H. Y., Lee, S., Blau, C. A., & Villén, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.050 · Cited by 225
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G., & Murphy, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 224
Explainable AI for clinical and remote health applications: A survey on tabular and time series data
Di Martino, F., & Delmastro, F. (2023) · Artificial Intelligence Review · doi:10.1007/s10462-022-10304-3 · Cited by 216
Integrative methods for analyzing big data in precision medicine
Gligorijević, V., Malod‐Dognin, N., & Pržulj, N. (2015) · PROTEOMICS · doi:10.1002/pmic.201500396 · Cited by 226
Fatty acid metabolism in breast cancer subtypes
Monaco, M. E. (2017) · Oncotarget · doi:10.18632/oncotarget.15494 · Cited by 216
Artificial Intelligence (AI)-Based Systems Biology Approaches in Multi-Omics Data Analysis of Cancer
Biswas, N., & Chakrabarti, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.588221 · Cited by 226
Amadou, A., Ferrari, P., Muwonge, R., Moskal, A., Biessy, C., Romieu, I., & Hainaut, P. L. (2013) · Obesity Reviews · doi:10.1111/obr.12028 · Cited by 215
An update on the pathological classification of breast cancer
Rakha, E. A., Tse, G. M.-K., & Quinn, C. (2022) · Histopathology · doi:10.1111/his.14786 · Cited by 215
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
Welte, T., Kim, I. S., Tian, L. H., Gao, X., Wang, H., Li, J., Holdman, X. B., Herschkowitz, J. I., Pond, A. C., Xie, G., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3355 · Cited by 217
Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer
Rak, J. W. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00021 · Cited by 216
NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis
Park, M. K., Zhang, L., Min, K., Cho, J.-H., Yeh, C., Moon, H., Hormaechea‐Agulla, D., Mun, H., Ko, S., Lee, J. W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.011 · Cited by 216
Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP
Shen, L., O’Shea, J. M., Kaadige, M. R., Cunha, S., Wilde, B. R., Cohen, A. L., Welm, A. L., & Ayer, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501555112 · Cited by 212
CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
Oshi, M., Asaoka, M., Tokumaru, Y., Yan, L., Matsuyama, R., Ishikawa, T., Endo, I., & Takabe, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186968 · Cited by 212
Neuronal substance P drives metastasis through an extracellular RNA–TLR7 axis
Padmanaban, V., Keller, I., Seltzer, E. S., Ostendorf, B. N., Kerner, Z. J., & Tavazoie, S. F. (2024) · Nature · doi:10.1038/s41586-024-07767-5 · Cited by 223
Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival
Ramazzotti, D., Lal, A., Wang, B., Batzoglou, S., & Sidow, A. (2018) · Nature Communications · doi:10.1038/s41467-018-06921-8 · Cited by 222
Metastatic progression of breast cancer: insights from 50 years of autopsies
Cummings, M. C., Simpson, P. T., Reid, L., Jayanthan, J., Skerman, J., Song, S., Reed, A. E. M., Kutasovic, J. R., Morey, A. L., Marquart, L., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4288 · Cited by 210
Tsimberidou, A. M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 210
Tumour heterogeneity and the evolutionary trade-offs of cancer
Hausser, J., & Alon, U. S. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0241-6 · Cited by 216
JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer
Yamamoto, S., Wu, Z., Russnes, H. G., Takagi, S., Peluffo, G., Vaske, C. J., Zhao, X., Vollan, H. K. M., Maruyama, R., Ekram, M. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.024 · Cited by 209
Self-citationProgesterone/RANKL Is a Major Regulatory Axis in the Human Breast
Tanos, T., Sflomos, G., Echeverría, P. C., Ayyanan, A., Gutierrez, M., Delaloye, J.-F., Raffoul, W., Fiche, M., Dougall, W. C., Schneider, P., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005654 · Cited by 214
Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer
Jiang, G., Zhang, S., Yazdanparast, A., Li, M., Pawar, A., Liu, Y., Inavolu, S. M., & Cheng, L. (2016) · BMC Genomics · doi:10.1186/s12864-016-2911-z · Cited by 210
bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses
Jézéquel, P., Gouraud, W., Azzouz, F. B., Guérin‐Charbonnel, C., Juin, P. P., Lasla, H., & Campone, M. (2021) · Database · doi:10.1093/database/baab007 · Cited by 209
Pareja, F. G., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 214
An omics perspective on drug target discovery platforms
Paananen, J., & Fortino, V. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz122 · Cited by 216
Johnstone, C. N., Smith, Y. E., Cao, Y., Burrows, A. D., Cross, R. S., Ling, X., Redvers, R. P., Doherty, J. P., Eckhardt, B. L., Natoli, A. L., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017830 · Cited by 214
Triple-Negative Breast Cancer and the Potential for Targeted Therapy
Jhan, J.-R., & Andrechek, E. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0117 · Cited by 205
Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
Linnekamp, J. F., Wang, X., Medema, J. P., & Vermeulen, L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2240 · Cited by 203
The recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.124 · Cited by 203
Regulators of genetic risk of breast cancer identified by integrative network analysis
Castro, M. A. A., de Santiago, I., Campbell, T. M., Vaughn, C. M., Hickey, T. E., Ross, E. M., Tilley, W. D., Markowetz, F. M., Ponder, B. A. J., & Meyer, K. B. (2015) · Nature Genetics · doi:10.1038/ng.3458 · Cited by 195
Self-citationOpposing Functions of BRD4 Isoforms in Breast Cancer
Wu, S.-Y., Lee, C.-F., Lai, H., Yu, C., Lee, J., Zuo, H., Tsai, S. Y., Tsai, M., Ge, K., Wan, Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.034 · Cited by 201
Greene, C. S., Tan, J., Ung, M. H., Moore, J. H., & Cheng, C. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24662 · Cited by 201
YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins
Agostino, S. D., Sorrentino, G., Ingallina, E., Valenti, F., Ferraiuolo, M. A., Bicciato, S., Piazza, S., Strano, S., Sal, G. D., & Blandino, G. (2015) · EMBO Reports · doi:10.15252/embr.201540488 · Cited by 200
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan, Z., Ding, Y., Kim, J.-H., Jung, H. H., Chung, W., Lal, S., Cho, S., Fernandez-Banet, J., Lee, S. K., Kim, S. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04129-4 · Cited by 200
A DNA methylation‐based definition of biologically distinct breast cancer subtypes
Stefánsson, Ó. A., Morán, S., Gómez, A., Sayols, S., Arribas-Jorba, C., Sandoval, J., Hilmarsdóttir, H., Ólafsdóttir, E. J., Tryggvadóttír, L., Jonasson, J. G., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.012 · Cited by 193
Taxonomy of breast cancer based on normal cell phenotype predicts outcome
Santagata, S., Thakkar, A., Ergonul, A. B., Wang, B., Woo, T. Y. C., Hu, R., Harrell, J. C., McNamara, G. T., Schwede, M., Culhane, A. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70941 · Cited by 192
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 199
Mihály, Z., Kormos, M., Lánczky, A., Dank, M., Budczies, J., Szász, M. A., & Győrffy, B. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2622-y · Cited by 190
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer
Damaskos, C., Valsami, S. I., Kontos, M. C., Spartalis, E. D., Kalampokas, T., Kalampokas, E., Athanasiou, A., Moris, D., Daskalopoulou, A., Davakis, S., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11286 · Cited by 190
Wagle, M.-C., Kirouac, D. C., Klijn, C. N., Liu, B., Mahajan, S., Junttila, M. R., Moffat, J. G., Merchant, M. A., Huw, L. Y., Wongchenko, M. J., et al. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0051-4 · Cited by 194
Tekpli, X., Lien, T. G., Røssevold, A. H., Nebdal, D. J. H., Borgen, E., Ohnstad, H. O., Kyte, J. A., Vallon‐Christersson, J., Fongaard, M., Due, E. U., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13329-5 · Cited by 193
Self-citationNLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer
Faria, S. S., Costantini, S., de Lima, V. C. C., Andrade, V. P., Rialland, M., Rébé, C., Budillon, A., & Magalhães, K. G. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00724-8 · Cited by 192
Targeting the cell cycle in breast cancer: towards the next phase
Thu, K. L., Soria‐Bretones, I., Mak, T. W., & Cescon, D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1502567 · Cited by 192
Metadata
- Authors
- METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Børresen-Dale, A.-L., Brenton, J. D., Tavaré, S., Caldas, C., & Aparicio, S.
- Affiliations
- University of Cambridge (GB)
- University of British Columbia (CA)
- Oslo University Hospital (NO)
- University of Nottingham (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- King's College London (GB)
- University of Southern California (US)
- Corresponding author
- Caldas, Carlos
- Aparicio, Samuel
- ORCID
- Curtis, Christina
- Shah, Sohrab P.
- Chin, Suet-Feung
- Turashvili, Gulisa
- Rueda, Oscar M.
- Dunning, Mark J.
- Speed, Doug
- Lynch, Andy G.
- Samarajiwa, Shamith
- Yuan, Yinyin
- Gräf, Stefan
- Ha, Gavin
- Haffari, Gholamreza
- Bashashati, Ali
- Green, Andrew
- Provenzano, Elena
- Wishart, Gordon
- Pinder, Sarah
- Watson, Peter
- Markowetz, Florian
- Murphy, Leigh
- Ellis, Ian
- Purushotham, Arnie
- Brenton, James D.
- Tavaré, Simon
- Caldas, Carlos
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-18
- Volume
- 486
- Issue
- 7403
- Pages
- 346-352
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3440846
- OpenAlex
- W2005895632
- Cited by
- 6,097
- References
- 32
- Citations by year
- 2026: 341 · 2025: 411 · 2024: 458 · 2023: 497 · 2022: 496 · 2021: 615 · 2020: 533 · 2019: 449 · 2018: 426 · 2017: 361 · 2016: 373 · 2015: 378 · 2014: 339 · 2013: 291 · 2012: 119
- FWCI
- 119.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Southern California
- Michael Smith Health Research BC
- Cancer Research UK (A7199, 15601, 19556)
- National Institute for Health and Care Research (ACF-2012-14-006, NF-SI-0611-10154)
- University of Cambridge
- King's College London
- National Institutes of Health
- BC Cancer Agency
- NIHR Cambridge Biomedical Research Centre
- National Human Genome Research Institute (P50-HG02790, P50HG002790)
- Division of Mathematical Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- breast cancer, copy number alterations, somatic copy number alterations, gene expression, single nucleotide polymorphisms, PPP2R2A, MTAP, MAP2K4, estrogen receptor-positive breast cancer, adaptive immune response, basal-like breast cancer, chromosome 5 deletion, molecular stratification, prognosis
- MeSH terms
- Breast Neoplasms, Female, Humans, Prognosis, Genome, Human, Gene Expression Regulation, Neoplastic, Treatment Outcome, Polymorphism, Single Nucleotide, Gene Expression Profiling, Genomics, MAP Kinase Kinase 4, Genes, Neoplasm, Kaplan-Meier Estimate, Gene Regulatory Networks, Protein Phosphatase 2, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
